<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489760</url>
  </required_header>
  <id_info>
    <org_study_id>CS08019</org_study_id>
    <nct_id>NCT02489760</nct_id>
  </id_info>
  <brief_title>Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study</brief_title>
  <official_title>Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung Shan Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chung Shan Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy of switch effects to adalimumab in etanercept-treated AS
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-centre, open-labeled randomized controlled study will evaluate the safety and
      efficacy of adalimumab in etanercept-treated Ankylosing Spondylitis(AS) patients.

      Thirty patients will be enrolled and randomized equally into two arms.

      Dosage and Administration：For standard dose(etanercept 50 mg weekly) treated patients, the
      treatment arm will receive adalimumab 40 mg subcutaneously biweekly for 8 weeks. The control
      arm will continue etanercept 25 mg subcutaneously twice a week for 8 weeks. At week 8, the
      control arm will be switched to adalimumab 40 mg subcutaneously biweekly for another 8
      weeks.For half dose(etanercept 25 mg weekly) treated patients, the treatment arm will receive
      adalimumab 40 mg subcutaneously monthly for 8 weeks. The control arm will continue etanercept
      25 mg subcutaneously weekly for 8 weeks. At week 8, the control arm will be switched to
      adalimumab 40 mg subcutaneously monthly for another 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bath AS disease activity index (BASDAI)</measure>
    <time_frame>weeks 8</time_frame>
    <description>The score of BASDAI on weeks 8</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Adalimumab switch to Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At week 8, the treatment arm will be switched to etanercept 25 mg subcutaneously biweekly for another 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept switch to Adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At week 8, the control arm will be switched to adalimumab 40 mg subcutaneously biweekly for another 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>The treatment arm will receive adalimumab 40 mg subcutaneously biweekly</description>
    <arm_group_label>Adalimumab switch to Etanercept</arm_group_label>
    <arm_group_label>Etanercept switch to Adalimumab</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>The control arm will continue etanercept 25 mg subcutaneously twice a week</description>
    <arm_group_label>Adalimumab switch to Etanercept</arm_group_label>
    <arm_group_label>Etanercept switch to Adalimumab</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AS, as defined by 1984 Modified New York Criteria for AS.

          -  Stable background therapy as non-steroid anti-inflammatory for 2 weeks.

          -  Stable glucocorticoid for 4 weeks.

          -  Stable disease-modifying anti-rheumatic drugs, eg. sulphasalazine, methotrexate for 8
             weeks.

          -  Stable anti-TNF biologics for 4 weeks.

          -  Written informed consent.

        Exclusion Criteria:

          -  Serum creatinine ≥3.0 mg/dl.

          -  GPT≥5 times the laboratory's upper limit of normal.

          -  Pregnant or breast-feeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei C- C, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chung Shan Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <last_update_submitted>January 18, 2016</last_update_submitted>
  <last_update_submitted_qc>January 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chung Shan Medical University</investigator_affiliation>
    <investigator_full_name>GCRC</investigator_full_name>
    <investigator_title>Etanercept versus Adalimumab in the Treatment of Patients with Ankylosing Spondylitis. A Switch Study.</investigator_title>
  </responsible_party>
  <keyword>Etanercept</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Ankylosing Spondylitis</keyword>
  <keyword>Switch Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

